Illumina Faces Order by EU Merger Watchdog to Sell Grail
- European Commission order could be issued in coming days
- Deal has sparked controversy and numerous court challenges
This article is for subscribers only.
European Union merger watchdogs are poised to deliver on their threat to order Illumina Inc. to sell cancer-test provider Grail Inc., undoing a $7 billion acquisition it closed without EU permission.
The EU decision could be issued in the coming days, according to a person familiar with the matter who spoke on condition of anonymity. It would be the biggest escalation in a long-running legal fight over the deal, which was vetoed by the European Commission last year over concerns the tie-up would hamper competition.